2 results
Approved WMOCompleted
The study aims to limit the use of anthracyclines and to reduce the dose of ATRA. Another aim is to stratify treatment by risk group: standard risk - WBC <10 x 109/l : high risk - WBC >=10 x 109/l. Furthermore this study aims to…
Approved WMORecruiting
Primary Part 1:-To evaluate ORR in participants treated with MK-4280A plus EV (Arm A), MK-7684A plus EV (Arm B), and pembrolizumab plus EV(Arm C) per RECIST 1.1 by BICR.- To evaluate the safety and tolerability in participants treated with MK-4280A…